Anti-CD79b [B29/123] mAb

Catalogue number: 151376
Sub-type: Primary antibody
Images:

Contributor

Inventor: Jacqueline Cordell
Institute: University of Oxford
Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Anti-CD79b [B29/123] mAb

Alternate name: CD79b Molecule; CD79B Antigen (Immunoglobulin-Associated Beta); Immunoglobulin-Associated B29 Protein; B-Cell-Specific Glycoprotein B29; Ig-Beta

Class: Monoclonal
Conjugate: Unconjugated
Description: The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling.
Purpose:
Parental cell:
Organism:
Tissue:
Model:
Gender:
Isotype: IgG2b
Reactivity: Human
Selectivity:
Host: Mouse
Immunogen: Synthetic peptide representing the c-terminus from residue 215 of the murine B29 polypeptide.
Immunogen UNIPROT ID:

Sequence:
Growth properties:
Production details:
Formulation:
Recommended controls:
Bacterial resistance:
Selectable markers:
Additional notes:

Target details

Target: CD79b

Target alternate names:

Target background: The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling.

Molecular weight:

Ic50:

Applications

Application: IHC ; WB
Application notes:

Handling

Format: Liquid
Concentration: 1 mg/ml
Passage number:
Growth medium:
Temperature:
Atmosphere:
Volume:
Storage medium:
Storage buffer: PBS with 0.02% azide
Storage conditions:

-15° C to -25° C
Shipping conditions: Shipping at 4° C

Related tools

Related tools:

References

References: HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimens. ; Arana et al. 2016. J Clin Pathol. :. PMID: 27484914. ; Delli et al. 2016. Ann Rheum Dis. :. PMID: 26757748. ; Towards personalised treatment in primary Sjgren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. ; Higashi et al. 2015. Leuk Lymphoma. :1-6. PMID: 25860238. ; Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma. ; Radaev et al. 2010. Structure. 18(8):934-43. PMID: 20696394. ; Structural and Fn studies of Igalphabeta and its assembly with the B cell antigen receptor. ; Boudova et al. 2006. J Cutan Pathol. 33(8):584-9. PMID: 16919035. ; Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman. ; Boudova et al. 2005. Am J Dermatopathol. 27(5):375-86. PMID: 16148405. ; Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients. ; Pilozzi et al. 1998. J Pathol. 186(2):140-3. PMID: 9924428. ; Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. ; Mason et al. 1995. Blood. 86(4):1453-9. PMID: 7632952. ; CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. ; Korkolopoulou et al. 1994. Histopathology. 24(6):511-5. PMID: 7520411. ; The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease.